SUMMARY Eight infants aged between 4 days and 12 weeks with severe heart failure that was refractory to optimal conventional treatment with diuretics were treated with enalapril. The starting dose was 0-1 mg/kg/day, increasing according to response to 0 12-O-43 mg/kg/day. One infant with severe myocarditis did not tolerate enalapril because of hypotension and later died of intractable heart failure. Six of the remaining patients had congenital systemic to pulmonary shunts and one had a simple aortic coarctation. Two weeks after starting enalapril the clinical features of heart failure had improved in all the infants, the mean (SEM) plasma sodium concentration had increased from 129 (2.4) to 136 (1.1) mmol/I and plasma urea concentration had fallen from 7*0 (0-85) to 2*9 (0.85) mmoL/l. These data suggest that enalapril is a potentially useful treatment for severe heart failure in infancy.
The standard treatment of heart failure in infancy comprises diuretics, either alone or in combination with digoxin. Digoxin has a narrow therapeutic range and its effectiveness as a postive inotropic agent texcept in the short term) is in considerable doubt. Over the past few years the introduction of angiotensin converting enzyme inhibitors has been an important advance in the treatment of heart failure in adults but their use in children has been limited. 2 3 We report the effect of enalapril in eight infants with heart failure that was refractory to treatment with diuretics.
Patients and methods
We report our total experience with enalapril for the treatment of heart failure in infancy between January 1986 and December 1987. Infants received enalapril if they had severe heart failure despite optimal diuretic treatment and corrective surgery was either not possible or considered inappropriate. The age at which enalapril was started ranged from 4 days to 12 weeks (median 3 weeks). Individual patient characteristics are shown in the table.
A suspension of enalapril was freshly prepared before each dose by dissolving a crushed 5 mg tablet in 5 ml sterile water. The appropriate dose was drawn up using a calibrated 1 ml syringe and given orally. Treatment Plasma urea and electrolytes were estimated 24 hours before starting enalapril, at least every 48 hours during the first week of treatment, and at least twice during the second week.
Clinical and biochemical data for the seven patients who survived at least two weeks after beginning enalapril are reported as mean (SEM).
Results
The clinical features of heart failure, drug treatment, and biochemistry 24 hours before enalapril and after two weeks treatment with enalapril are documented for each patient in the table. The time course of weight gain, increase in plasma sodium mg/kg/day (range 0-9-3-2) to 0*7 mg/kg/day (range 0-1-8). Two patients were given chlorthiazide instead of frusemide and five patients were given oral instead of intravenous frusemide.
The mean weight increased from 3*3 (0.24) kg to 3*6 (0-29) kg after two weeks taking enalapril. Four of the seven infants required nasogastric feeding before the introduction of enalapril, but by two weeks two of these had progressed to full bottle feeds. The mean daily feed volume increased from 135 (10.5) to 159 (5.6) ml/kg/day.
Mean plasma sodium concentration was 129 (2-4) mmol/l (range 124-138) before treatment with enalapril and was abnormally low in five of the seven patients. At two weeks the plasma sodium concentration was within the normal range in all seven patients, mean 136 (1-1) mmol/I (range 135-140). The plasma potassium concentration was 4-6 mmol/I (range 3-5-5.3) before starting enalapril and was unchanged after two weeks. No patients required potassium sparing diuretics or potassium supplements after starting enalapril. The mean plasma urea concentration was 7 0 (0.85) mmoIIl (range 5-11-6) before starting enalapril and fell in all seven patients to a mean of 2*9 (0-85) mmol/l (range 1-.07-7) after two weeks.
Discussion
Captopril and enalapril have gained widespread acceptance for the treatment of hypertension and heart failure in adults. There are only two reports on the use of captopril for the treatment of heart failure in infants2 3 and none of enalapril. The drugs differ structurally but both inhibit angiotensin converting enzyme, also known as kininase 1I.4 This enzyme catalyses two important processes: the conversion of angiotensin I to angiotensin II, and the breakdown of bradykinin, a potent vasodilator agent. Angiotensin II is a potent vasoconstrictor and also stimulates the release of aldosterone from the adrenal cortex. Inhibition of the enzyme by captopril or enalapril thus leads to vasodilatation and inhibition of salt and water retention in the kidneys.
Previous studies have reported improvement in infants with heart failure treated with captopril.2 3 Enalapril has the advantage of a once daily regimen as compared with a three times daily regimen for captopril. As both drugs have to be freshly prepared before each dose, a once daily regimen is time saving for the nurses. Enalapril4prolongs survival in adults with severe heart failure, but it is not known whether captopril does so. On the other hand, the long half life of enalapril may result in a delayed and prolonged hypotensive effect after the first dose,5 and the time to reach a steady state is longer.
Whereas the underlying problem in adults with heart failure is usually pump failure, in infancy it is usually volume overload as a result of large systemic to pulmonary shunts. In the former case the beneficial effects of enalapril are thought to be caused by a combination of afterload reduction and long term inhibition of salt and water retention, though in the early days of treatment net salt and water retention may occur as a result of the acute effects of enalapril on renal blood flow.6 In infants with large systemic to pulmonary shunts the causes of heart failure may be more complex. Pulmonary vascular resistance falls progressively after birth and infants with severe heart failure usually have comparatively normal pulmonary vascular resistance.7 In contrast, high catecholamine and angiotensin II concentrations as a consequence of severe heart failure usually result in high systemic vascular resistance.7 Under these circumstances enalapril might be expected to have a much greater effect on systemic than on pulmonary vascular resistance. The impressive clinical response to enalapril in our patients with shunts suggests that systemic vascular resistance fell more than pulmonary vascular resistance, resulting in an increase in systemic blood flow and a decrease in the size of the left to right shunt.
There was a pronounced and sustained clinical improvement in six of the eight patients, five of whom had large systemic to pulmonary shunts and one who had aortic coarctation. One infant (case 2) improved to such an extent that pulmonary artery banding, which had seemed inevitable, was avoided. The large ventricular septal defect responsible for this patient's heart failure has subsequently closed spontaneously, thus avoiding the need for surgery. Though case 3 did not improve after treatment with enalapril, and indeed died one week after its introduction, we believe that this was the result of progressive myocardial failure rather than an adverse effect of enalapril. Prolonged hypotension, however, is a potentially important problem that requires close monitoring of the response to treatment, particularly immediately after the first dose. One further patient had died (case 7) but this infant initially improved on enalapril, which was withdrawn after corrective surgery. The cause of death was septicaemia, acute renal failure, and worsening heart failure.
The response of the plasma sodium concentration is of some interest. Hyponatraemia is a marker of severe heart failure and is associated with high concentrations of both renin and antidiuretic hormone.8
Hyponatraemia in association with heart failure is a consequence of water overload, and the total body sodium concentration may be normal or high rather than low. 10 The response of our patients with hyponatraemia is encouraging, and suggests that the use of enalapril may reduce the need for severe fluid restriction. The mechanisms of reversal of hyponatraemia may be complicated, but probably entail an improvement in haemodynamics or a reduction in the direct antidiuretic hormone like activity of angiotensin II and the angiotensin II mediated release of antidiuretic hormone.11 12 The mean plasma urea concentration fell for the group as a whole, but rose in a single patient. A deterioration in renal function in adult patients given enalapril during the treatment of heart failure is common.6 This is thought to be associated with both a reduction in central systemic blood pressure and a decrease in transglomerular perfusion pressure. The improvement in renal function in our patients during the first two weeks of treatment suggests that the improvement in systemic blood flow and the decreased diuretic requirement with enalapril outweigh the potentially deleterious effects of enalapril on renal function.
In summary, our small study suggests that enalapril may offer a new and exciting alternative treatment for severe heart failure in infancy, particularly in patients with large systemic to pulmonary shunts. This may permit surgery to be delayed until the infant is in better condition, and temporary pulmonary artery banding may be avoided in some cases. Larger studies are required to confirm our findings and to identify possible adverse effects.
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